Geode Capital Management’s Ocera Therapeutics, Inc. OCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-57,658
| Closed | -$65K | – | 4077 |
|
|
2017
Q3 | $65K | Hold |
57,658
| – | – | ﹤0.01% | 3899 |
|
|
2017
Q2 | $66K | Sell |
57,658
-3,970
| -6% | -$4.61K | ﹤0.01% | 3912 |
|
|
2017
Q1 | $80K | Buy |
61,628
+540
| +0.9% | +$688 | ﹤0.01% | 3868 |
|
|
2016
Q4 | $128K | Buy |
61,088
+360
| +0.6% | +$840 | ﹤0.01% | 3737 |
|
|
2016
Q3 | $160K | Buy |
60,728
+90
| +0.1% | +$225 | ﹤0.01% | 3670 |
|
|
2016
Q2 | $115K | Hold |
60,638
| – | – | ﹤0.01% | 3766 |
|
|
2016
Q1 | $178 | Sell |
60,638
-90
| -0.1% | -$257 | ﹤0.01% | 3669 |
|
|
2015
Q4 | $189K | Buy |
60,728
+180
| +0.3% | +$615 | ﹤0.01% | 3703 |
|
|
2015
Q3 | $191K | Sell |
60,548
-2,424
| -4% | -$9.33K | ﹤0.01% | 3696 |
|
|
2015
Q2 | $239K | Buy |
62,972
+14,115
| +29% | +$54.1K | ﹤0.01% | 3517 |
|
|
2015
Q1 | $230K | Buy |
48,857
+36,378
| +292% | +$210K | ﹤0.01% | 3528 |
|
|
2014
Q4 | $79K | Buy |
12,479
+818
| +7% | +$4.79K | ﹤0.01% | 3823 |
|
|
2014
Q3 | $57K | Buy |
+11,661
| New | +$67.3K | ﹤0.01% | 3824 |
|
|
2013
Q3 | – | Sell |
-4,140
| Closed | -$23K | – | 3665 |
|
|
2013
Q2 | $23K | Buy |
+4,140
| New | +$25.7K | ﹤0.01% | 3585 |
|
Geode Capital Management's OCRX Position: Q4 2017 in Review
Geode Capital Management sold out of Ocera Therapeutics, Inc. (OCRX) in Q4 2017, closing a stake of 57,658 shares — an estimated $65K sold.
Geode Capital Management first reported a position in OCRX in Q2 2013 and held it in 14 quarters. The position peaked at $239K in Q2 2015. 0 funds tracked by Wall St. Rank hold OCRX as of Q4 2017.
- Geode Capital Management reported no remaining Ocera Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
- Geode Capital Management sold 57,658 Ocera Therapeutics, Inc. shares in Q4 2017, an estimated $65K.
- Geode Capital Management first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
- Geode Capital Management's Ocera Therapeutics, Inc. position peaked at $239K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q4 2017.
Based on Geode Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.